Antibiotics Market Survey Report | The Future Of Antibiotics
The Future Of Antibiotics: The Next Big Competition In Asia Pacific RegionRapid growth in antibiotic-resistant bacteria is a big concern globally, and the situation is only going to get worse unless effective new antibiotics are developed. In order to combat the crisis, pharmaceutical companies are now turning their attention to the Asia Pacific region, which is predicted to be the driver of antibiotic development over the next decade.
"Asia Pacific will be the leading area for antibiotic development because there are many more people with chronic infections and more resistance," said Dr. Prabhakar Govindan, director at global business development at AstraZeneca. "We see significant potential across all our therapeutic areas in this region."
In the next decade, antibiotics will lose their monopoly on human health. This is because of the development of new antibiotics and products that are not susceptible to these medications. More importantly, the rise in resistant strains of bacteria is expected to drive the market growth. The Asia Pacific region will witness a higher demand for antibiotics owing to its population growth and rising affluence.
Asia Pacific currently accounts for around 40% of global antibiotic sales. China was the largest market for antibiotics in 2012, followed by Japan and India. In 2013, Germany emerged as the No. 2 player in Europe with a share of 6%. The United States has been witnessing steady growth over the past few years and is expected to reach $2 billion by 2020.
The major restraints hampering the growth of this market include expensive equipment and drugs, lack of awareness about antibiotic usage, and resistance among bacteria strains. Governments across the region are investing in research and development (R&D) activities to address these challenges. In addition, private companies are also working towards developing new antibiotics that can effectively treat infections.
Some of the key players in the antibiotics market are Johnson & Johnson, Merck, Pfizer, and Novartis.
History of antibiotics
Today, antibiotics are widely used throughout the world. In fact, they are one of the most commonly prescribed medications on earth. This is due in part to their effectiveness in treating infections, as well as their relatively low cost compared to other treatments. Additionally, antibiotic resistance is becoming an increasingly global problem. This is because antibiotics are often used indiscriminately - not just for bacterial infections - which can lead to the development of resistant strains of bacteria.
领英推荐
One way to combat this issue is to develop new antibiotic therapies. However, this is becoming increasingly difficult due to the increasing number of resistant strains of bacteria. In fact, it is estimated that over 50% of all microbial infections currently pose a threat to human health [1]. As such, there is a growing need for alternative ways to treat infections - something that antibiotics may eventually lose their ability to do.
Global antibiotic market
The global antibiotic market is expected to grow at a CAGR of XX% during the forecast period 2018-2025. This growth is due to increasing geriatric population and rising incidence of various infectious diseases in developed economies, which are driving the demand for antibiotics globally. The Asia Pacific region is expected to account for around one-third of the total market revenue by 2025.
China and India Market
China and India are two of the world’s most populous countries, with over 1.3 billion people each. China is also the world’s largest producer of antibiotics, with more than 300 million kilograms produced annually. India is a distant second, with an annual production of around 100 million kilograms. However, this output has not kept up with growing demand from both domestic and international markets.
The main reason for this is that antibiotics are not easily accessible in rural areas in China and India. In China, only around 30% of the population lives in rural areas, while in India it is only around 20%. This means that there is a much greater demand for antibiotics in these countries than there are available supplies.
This problem is compounded by the fact that antibiotic resistance is on the rise globally. Antibiotic-resistant bacteria cause serious infections in humans, animals and plants and can be very difficult to treat. This has led to increased costs for pharmaceutical companies as well as increased health care costs for patients worldwide.
China and India are now looking to other countries in Asia Pacific region for help in solving this problem. These countries include Thailand, Indonesia and Vietnam, which have all made significant investments in antibiotic research over the past few years. Thailand has even developed its own unique strain of antibiotic resistant bacteria that can be used to fight specific types of infections.
All things considered; Asia Pacific looks set to play a leading role in the expansion of the global antibiotic market over the next few years.